Journal articleLancet Gastroenterol Hepatol2024

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.

DOI 10.1016/s2468-1253(23)00405-3 ↗ Europe PMC, retrieved 5 November 2026

Journal: Lancet Gastroenterol Hepatol
Published: 15 January 2024
Citations: 185

These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Trials 3

Its registry lists this paper as resultsNordic Pancreatic Cancer Trial (NorPACT) - 1 NCT02919787 ↗
BackgroundNeoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer NCT07081360 ↗
BackgroundPrediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer NCT07226154 ↗

The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.